Member Info for Laura2022

5 new contracts plus recommenced Merck revenues (€500,000 annually)

Hired 3 new personal to drive the business forward

Main points from the annual report below :

The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering.

Device to measure blood counts

Feedback from clinicians suggests that enabling patients to undergo these diagnostic tests in a primary care or home setting would facilitate use of our tool and as such we are actively exploring opportunities to work with Beyond Blood.

Collaborations

we are open to and continue to explore other approaches including risk sharing and collaboration. An example of this includes the risk-sharing deal with ValiRx plc announced in February 2021 for which terms have been fully disclosed and which would be triggered by the receipt by ValiRx of licensing revenues related to VAL-201

Not quite sure why semantic has posted given his last posts were all on the failed NNN 6mths ago

Maybe read all all RNSs

Filtered

Totally agree Acker Brighty etc

》bio statistics

》UK government project(such the Nov 10th RNS today)

They raised £390k in June and also had £400k in the bank ,as they are a software company their over heads are low , the £790k is good for the foreseeable future (see Sept 2023 annual report)

The potential £6mln( not all at once ) VAL201 could be nearing a conclusion in next weeks or so (see VAL merger information which triggers the out licence of VAL201 which PYC gain from having done the modelling

The DoseMeRx USA deal potentially integrating PYC dosing tool Into a multi $mln US market

The personalised/A.I capabilities

The £1mln+ pipeline of pre-checked deals /contracts on top of the c £300k+ won since July 2023 (estimates )

The move into bio statistics

All for £1.9mln market value

Physiomics CEO, Dr Jim Millen, commented:

"We are delighted to have won our fourth Innovate UK award, which we believe is a testimony to the innovative culture of our company. This grant gives us a unique opportunity to capitalise on previous grant-funded work in the personalised oncology space, as well as foster our collaboration with Beyond Blood Diagnostics Ltd, and we are looking forward to working with new partner, Blackpool Teaching Hospitals NHS Foundation Trust."

 

Company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a grant by Innovate UK and The Office for Life Sciences as part of the UK Government's Advancing Precision Medicine programme.  The grant-funded project is called "PREDICT-ONC: Precision Risk Evaluation and G-CSF Dosing for Chemotherapy-Induced Neutropenia Tool" (the "Project" or "PREDICT-ONC") and will be carried out in partnership with Beyond Blood Diagnostics Limited ("Beyond Blood Diagnostics") and Blackpool Teaching Hospitals NHS Foundation Trust ("Blackpool Teaching Hospitals").  The Project's total costs, shared between the three partners, are expected be £570,651, of which Physiomics' costs are expected to be £196,251 (primarily comprising staff salaries).  The Project costs are 70% funded by the grant, hence Physiomics will receive £137,376 over the course of the Project which will start immediately and is expected to run until October 2025

Thanks msuk

What does BO stand for

This afternoon

Given that PYC CEO is part of VAL advisory committe (see Feb 2021 VAL PYC RNS) i would beg to differ

But I take your comment that PYC cannot comment until Val do

Thanks

I'm in at 11p this week

From Feb 2021

According the VAL board over the last few weeks of Oct/Nov 2023 they are looking at a £60mln deal for VAL 201

From Feb 2021

Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus i

Ozay

Worth reading the last 3mths of RNS

Here is a brief summary

Acker msuk etc4 Nov 2023 11:00

Of more importance is the fundamental disconnect

The new appointment made to the PYC company are involved in growing sectors of

》artificial intelligence

》 predictive mathematic modelling

》bio statistics

They raised £390k in June and also had £400k in the bank ,as they are a software company their over heads are low , the £790k is good for the foreseeable future (see Sept 2023 annual report)

The potential £6mln( not all at once ) VAL201 could be nearing a conclusion in next weeks or so (see VAL merger information which triggers the out licence of VAL201 which PYC gain from having done the modelling

The DoseMeRx USA deal potentially integrating PYC dosing tool Into a multi $mln US market

The personalised/A.I capabilities

The £1mln+ pipeline of pre-checked deals /contracts on top of the c £300k+ won since July 2023 (estimates )

The move into bio statistics

All for £1.9mln market value

Hi ozay

Yes we grt £6mn as per Feb 2021 Rns

Thanks msuk

Please could you do a chart for a comapny called RQIH please and post it there

50% rise is quite easily possible

Good morning Trench/Ackers

I have emailed pyc to see if we can get a newsletter on any recent deveopment (eg nov 6th conference) and asked if possible if we can update on DoseMeRx and the VAL imminent merger

Germany on November 6-8th

 

Physiomics’ Chief Operating Officer, Dr Pete Sargent and Head of Business Development, Hayley Close will be attending the event. The aim is to engage with leaders from across the BioPharma industry to explore opportunities for collaboration that can benefit from the Company’s breadth of experience in mathematical modelling, simulation and biostatistics.

 

You do wonder why someone buys 85,000 shares then sells them 10misn late in 4 lots (25,25,25,12)

Seems very cheap and the drop overdone from 60p to 11p

I have purchased £7,000